Views: 1,414 | Downloads:
21
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Short Term Evaluation of Captopril in Patients with Chronic Left Sided Valvular Regurgitations
Jirasirirojanakorn K 
,
Mahanonda N ,
Jootar P ,
Chaithiraphan S ,
Wansanit K ,
Watanaprakarnchai W
,
Mahanonda N ,
Jootar P ,
Chaithiraphan S ,
Wansanit K ,
Watanaprakarnchai W Objective: To evaluate the clinical effects and the changes in cardiac performance of highand
low-dose captopril compared to placebo in patients with chronic symptomatic aortic regurgitation
(AR), and/or mitral regurgitation (MR).
Patients and Methods: We randomized patients into three groups, placebo (Group 1), incremental
daily doses of 50 mg (Group 2), and 100 mg captopril (Group 3). We compared exercise
capacity before and after four-week of treatment.
Results: Treatment was well tolerated with no serious side effects including blood
chemistry. There were no significant effects of treatment on left ventricular dimensions nor calculated
left ventricular ejection fraction (LVEF) between groups (LVEF change -0.6%, -2.6%,
2.4%, in group 1, 2 and 3 respectively; p > 0.05). No difference of exercise duration between
treatment and placebo arms (change by 13%, 12.8%, 16.4%, respectively; p > 0.05). However, there
were trends in the number of the patients who improved in left ventricular performance (absolute
LVEF change > 5 % unit= 15%, 16%, and 42% respectively; p > 0.05) and exercise performance
(exercise time improvement > 75 sec = 50%, 47%, and 68% respectively; p > 0.05) in high dose
captopril treatment group.
Conclusion: There was no significant improvement of left ventricular performance and
exercise capacity after four-weeks' treatment of low and high dose captopril. Further study with
a larger sample size, and longer follow-up period may be required.
low-dose captopril compared to placebo in patients with chronic symptomatic aortic regurgitation
(AR), and/or mitral regurgitation (MR).
Patients and Methods: We randomized patients into three groups, placebo (Group 1), incremental
daily doses of 50 mg (Group 2), and 100 mg captopril (Group 3). We compared exercise
capacity before and after four-week of treatment.
Results: Treatment was well tolerated with no serious side effects including blood
chemistry. There were no significant effects of treatment on left ventricular dimensions nor calculated
left ventricular ejection fraction (LVEF) between groups (LVEF change -0.6%, -2.6%,
2.4%, in group 1, 2 and 3 respectively; p > 0.05). No difference of exercise duration between
treatment and placebo arms (change by 13%, 12.8%, 16.4%, respectively; p > 0.05). However, there
were trends in the number of the patients who improved in left ventricular performance (absolute
LVEF change > 5 % unit= 15%, 16%, and 42% respectively; p > 0.05) and exercise performance
(exercise time improvement > 75 sec = 50%, 47%, and 68% respectively; p > 0.05) in high dose
captopril treatment group.
Conclusion: There was no significant improvement of left ventricular performance and
exercise capacity after four-weeks' treatment of low and high dose captopril. Further study with
a larger sample size, and longer follow-up period may be required.
Download:
PDF